Matching Perfusion and Metabolic Activity in HFpEF
Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18+
SponsorUniversity of Pennsylvania
About this trial
This study will test whether pharmacologic agents that increase perfusion \[Potassium Nitrate (KNO3)\], with and without additional supplements that may improve mitochondrial function \[Propionyl-L-Carnitine (PLC) and Nicotinamide Riboside (NR)\], improve submaximal exercise endurance and skeletal muscle oxidative phosphorylation capacity (SkM OxPhos) in participants with Heart Failure with Preserved Ejection Fraction (HFpEF).
Eligibility criteria
Qualifiers
NYHA Class II-III symptoms
Left ventricular ejection fraction >= 50%
Stable medical condition for at least 2 weeks, as per investigator judgment
Disqualifiers
Age <18 years old
Treatment with organic nitrates or phosphodiesterase inhibitors that cannot be interrupted
Uncontrolled atrial fibrillation, as defined by a resting heart rate > 100 beats per minute at the time of the baseline assessment
Hemoglobin < 10 g/dL
Trial design
Treatments tested in this trial
- Potassium Nitrate
- Potassium Nitrate + Propionyl-L-Carnitine + Nicotinamide Riboside
- Potassium Chloride
Treatment groups
53 Participants
are divided into 3 treatment groupsLocations
1University of Pennsylvania19104, PhiladelphiaPennsylvania, United States
Sponsors and collaborators
University of Pennsylvania
Lead sponsor
Source ClinicalTrials.gov